CTRI/2021/12/038550
Recruiting
未知
KAP evaluation of Psoriasis disease and its Nutritional Management among Psoriasis patients
Dr Braj Bhushan Kumar0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: L405- Arthropathic psoriasisHealth Condition 2: L401- Generalized pustular psoriasisHealth Condition 3: L404- Guttate psoriasisHealth Condition 4: L408- Other psoriasisHealth Condition 5: L400- Psoriasis vulgarisHealth Condition 6: L409- Psoriasis, unspecifiedHealth Condition 7: L403- Pustulosis palmaris et plantaris
- Sponsor
- Dr Braj Bhushan Kumar
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with psoriasis for more than 6 months, on regular conventional treatment, willingly ready to be included in the research
Exclusion Criteria
- •Patients who have been receiving any systemic therapy or photo\-therapy shall be included only after 4 weeks of washout period is passed. Patients with serious life\-threatening co\-morbidity, irregular and drop\-outs etc. shall also not be included in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
An Assessment of the Prevalence of Psoriasis in Patients with Hepatitis Cchronic skin disease with increased keratinizationpsoriasis10011063NL-OMON34745Academisch Medisch Centrum80
Not yet recruiting
Not Applicable
To study the predominance of ekakustha(psoriasis) in prespective to deha pakritiCTRI/2022/01/039547Shri NPA Govt Ayurved college Raipur Chhattisgarh
Completed
Not Applicable
A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser (PDL) in the Treatment of Nail PsoriasisNail PsoriasisNCT03946826xjpfW20
Completed
Phase 3
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsPsoriasisNCT04435600AbbVie139
Active, not recruiting
Not Applicable
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CarePsoriasisNCT04780516AbbVie141